Bio Medica Laboratories Ltd.
BIOMEDSME
Ask IPO
Overview
Bio Medica Laboratories Limited manufactures pharmaceutical parenteral formulations, focusing on generic liquid injections and dry powder injections for both human and veterinary use. Bio Medica Laboratories Limited operates primarily on a B2B contract manufacturing model, producing formulations to client specifications and allowing customers to market products under their own brands. The company operates manufacturing facilities in Indore, Madhya Pradesh, holds GMP and GLP certifications from the Food & Drugs Administration, Madhya Pradesh, and supports production with in-house quality control and laboratory capabilities including HPLC, GC and other analytical instruments.
Opening Date
May 21, 2026
Closing Date
May 25, 2026
Listing Date
May 29, 2026
IPO Type
SME
IPO Status
Closed
Issue Size
52.43 Cr
Fresh Issue
47.19 Cr
Offer for Sale
5.24 Cr
Price Band
₹132 - ₹139
Lot Size
1000
IPO Timeline
Financials
Revenue
Profit After Tax (PAT)
IPO Objective
The main objectives of the issue are to strengthen the balance sheet, expand manufacturing infrastructure, and support broader corporate requirements.
- •
Repay or prepay certain outstanding borrowings amounting to approximately Rs. 650.00 lakhs, which is expected to reduce debt levels, lower finance costs, improve the debt-equity position, and enhance financial flexibility for future growth.
- •
Enhance existing production capabilities by setting up a new manufacturing facility at Manufacturing Unit II in Indore, including civil construction and installation of new plant and machinery for injectable pharmaceutical products, with an estimated allocation of about Rs. 2,850.00 lakhs from the issue proceeds.
- •
Meet general corporate purposes, including strategic initiatives, strengthening the marketing network and brand visibility, supporting operational exigencies, and providing flexibility for business growth, subject to regulatory limits on such utilization.
- •
Achieve the benefits of listing on the NSE Emerge platform, including improved corporate visibility, stronger brand positioning, and creation of a public market for the company’s equity shares in India.
Key Performance Indicator
P/E Ratio
13.03
EPS
10.67
ROE
54.41%
ROCE
23.22%
RONW
54.41%
Debt to Equity Ratio
—
PAT Margin
30.35%
EBITDA Margin
47.11%
P/B
8.66
SWOT Analysis
Strengths
- •
Established manufacturer of pharmaceutical parenteral formulations with liquid and dry powder injectable product capabilities.
- •
B2B contract manufacturing model enables production tailored to customer specifications across human and veterinary segments.
- •
GMP and GLP certifications supported by in-house laboratory infrastructure and quality control systems.
- •
Planned capacity expansion at the existing Indore unit can strengthen scale and operational efficiency.
Weaknesses
- •
Business is concentrated in injectable formulations, limiting diversification across broader pharmaceutical dosage forms.
- •
Operations and revenues are largely India-focused, increasing dependence on domestic economic and regulatory conditions.
- •
High working capital intensity is reflected in significant inventory and receivables levels.
- •
Promoter concentration and related overlapping pursuits within promoter group entities may create governance or conflict concerns.
Opportunities
- •
Rising demand for sterile injectables, critical-care medicines and contract manufacturing in the Indian pharmaceutical market.
- •
New manufacturing facility and equipment additions can expand production capacity and product range.
- •
Debt repayment from IPO proceeds can reduce finance costs and improve profitability and balance sheet strength.
- •
Ability to serve both human and veterinary markets creates room for wider customer acquisition and product penetration.
Threats
- •
Stringent pharmaceutical quality, environmental and manufacturing regulations can increase compliance costs or disrupt operations.
- •
Raw material sourcing risks, including imported inputs, may affect cost structure and supply continuity.
- •
Intense competition from other pharmaceutical manufacturers and contract manufacturers can pressure margins.
- •
Natural disasters, geopolitical disruptions, inflation or broader economic slowdown in India could adversely affect business performance.
Subscription Rate
Frequently Asked Questions about Bio Medica Laboratories Ltd.
Bio Medica Laboratories Limited manufactures pharmaceutical parenteral formulations, focusing on generic liquid injections and dry powder injections for both human and veterinary use. Bio Medica Laboratories Limited operates primarily on a B2B contract manufacturing model, producing formulations to client specifications and allowing customers to market products under their own brands. The company operates manufacturing facilities in Indore, Madhya Pradesh, holds GMP and GLP certifications from the Food & Drugs Administration, Madhya Pradesh, and supports production with in-house quality control and laboratory capabilities including HPLC, GC and other analytical instruments.
The Bio Medica Laboratories Ltd. IPO is scheduled to open for subscription on May 21, 2026 and close on May 25, 2026. Investors can apply for shares during this period through eligible platforms.
The price band for the Bio Medica Laboratories Ltd. IPO is ₹132 to ₹139. Investors can place bids within this range once the issue opens.
The minimum lot size for the Bio Medica Laboratories Ltd. IPO is 1000 shares. The minimum investment amount ₹1,39,000.
The total issue size of the Bio Medica Laboratories Ltd. IPO is approximately ₹52.43. Issue size represents the total value of shares offered to the public.
As per the latest available information, the Bio Medica Laboratories Ltd. IPO has been subscribed 1.01 times. Subscription levels can change significantly during the offer period.
The Grey Market Premium (GMP) for the Bio Medica Laboratories Ltd. IPO is not available as of now. GMP reflects unofficial market sentiment and should not be considered a guarantee of listing performance.
The shares of Bio Medica Laboratories Ltd. are expected to list on stock exchanges on May 29, 2026, subject to completion of the allotment process and regulatory approvals.
The net proceeds from the Bio Medica Laboratories Ltd. IPO are proposed to be used for The main objectives of the issue are to strengthen the balance sheet, expand manufacturing infrastructure, and support broader corporate requirements., Repay or prepay certain outstanding borrowings amounting to approximately Rs. 650.00 lakhs, which is expected to reduce debt levels, lower finance costs, improve the debt-equity position, and enhance financial flexibility for future growth., Enhance existing production capabilities by setting up a new manufacturing facility at Manufacturing Unit II in Indore, including civil construction and installation of new plant and machinery for injectable pharmaceutical products, with an estimated allocation of about Rs. 2,850.00 lakhs from the issue proceeds., Meet general corporate purposes, including strategic initiatives, strengthening the marketing network and brand visibility, supporting operational exigencies, and providing flexibility for business growth, subject to regulatory limits on such utilization., Achieve the benefits of listing on the NSE Emerge platform, including improved corporate visibility, stronger brand positioning, and creation of a public market for the company’s equity shares in India.
Before applying for the Bio Medica Laboratories Ltd. IPO, investors generally review the company’s business model, financial performance, valuation, industry outlook, and risk factors mentioned in the offer document.
